Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.56 |
| ▸ | HTR7 | P34969 | 9/20 | 0.54 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17673584 | 0.92 | KMO (0.53) | KMOHTR7EGFRKDM4EALDH1A1 | |
| SCHEMBL17678223 | 0.89 | KMO (0.58) | KMOHTR7EGFRMCHR1 | |
| SCHEMBL17673722 | 0.86 | EGFR (0.56) | KMOHTR7EGFRALDH1A1MAPT | |
| SCHEMBL17678219 | 0.81 | KMO (0.56) | KMOHTR7EGFRMCHR1HTR2A | |
| SCHEMBL17678119 | 0.80 | EGFR (0.58) | KMOEGFRKDM4EALDH1A1P2RX7 | |
| SCHEMBL7258361 | 0.78 | KMO (0.53) | KMOHTR7EGFRMCHR1HTR2A | |
| SCHEMBL17678016 | 0.77 | KMO (0.52) | KMOEGFRMAPTMCHR1HTR2A | |
| SCHEMBL17673818 | 0.77 | KMO (0.66) | KMOHTR7EGFRHTR2AHTR2C | |
| SCHEMBL385334 | 0.77 | MCHR1 (0.50) | HTR7EGFRMCHR1 | |
| SCHEMBL24148142 | 0.76 | KMO (0.64) | KMOHTR7EGFRHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. | 2019-05-23 | — | — | US | disclosed |
| EP-3204009-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BioMarin Pharmaceutical Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A9 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
| WO-2016057834-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151312-A1 | HEPARAN SULFATE BIOSYNTHESIS INHIBITORS FOR THE TREATMENT OF DISEASES | HPSE, GAA, MAN2B1 | KMO 2987/4885HTR7 3188/4885EGFR 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.